Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 09 July 2012 | By Alexander Gaffney, RAC
The European Medicines Agency (EMA) on Friday, 6 June issued an updated guideline on the investigation of drug-drug interactions, giving the guidance its first "major revision" since 1998.
The guidance addresses the "potential for pharmacokinetic interactions between new medicinal products and already marketed drugs" and other products-including food-and how to best address drug-drug interactions (DDI) through in vitro and in vivo studies. DDIs are commonly associated with adverse events, and EMA said they are a common cause of hospital admissions and patient deaths.
EMA regulators said the updated document "outlines a comprehensive, systematic and mechanistic approach to the evaluation of the interaction potential of a drug during its development and offers guidance to ensure that the prescriber receives clear information on the interaction potential as well as practical recommendations on how the interactions should be managed during clinical use."
"Today's update brings the guideline in line with scientific advances in the investigation of drug interactions," EMA explained. "These include the ability to predict clinically relevant drug interactions from a limited number of well-designed studies, as well as progress in understanding of enzyme induction and drug-transporter interactions in recent years."
Sponsors of drug applications should assess pharmacodynamic interactions between drugs "which compete with each other" at the target site and if "drug are likely to be used concomitantly."
Pharmacokinetic interactions should be assessed using in vitro and in vivo studies, and EMA notes animal studies will usually not be relevant "due to the marked species differences," making the extrapolation of collected data "difficult." ADME studies-absorption, distribution, metabolism and excretion-should also be conducted, and EMA's guideline provides extensive instruction about which factors to consider when conducting such tests.
EMA also notes DDI studies should usually be conducted in healthy adults unless it is necessary to include patients for tolerability or safety reasons. These studies should be performed using validated probe drugs, which are drugs metabolism by one specific enzyme or transporter, which should allow for the effect of the second drug to be easily noted. These so-called "cocktail studies" involving probe drugs are also extensively covered in the guideline, and EMA provides a list of accepted probe drugs in an attached appendix.
"The clinical relevance of the effects of the studied drugs on the pharmacokinetics of the investigational drug should be assessed and the results used to predict the effects of other drugs where a similar interaction by the same mechanism can be expected," EMA writes in its guideline. "Treatment recommendations should ensure that patients receive drug treatment which is effective and safe."
The updated guideline comes into effect 1 January 2013.
Read more:
EMA - Guideline on the Investigation of Drug Interactions
EMA - European Medicines Agency updates guideline on drug interactions
Tags: Drug-Drug Interactions, DDI, ADME, Latest News, pharmaceutical, guideline, drug
Regulatory Focus newsletters
All the biggest regulatory news and happenings.